Cardiology in Review最新文献

Pompe Disease: Current State and Future Treatments. 庞贝病：当前状态和未来治疗。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-02 DOI: 10.1097/CRD.0000000000000980

Margot Richards, William H Frishman

{"title":"Pompe Disease: Current State and Future Treatments.","authors":"Margot Richards, William H Frishman","doi":"10.1097/CRD.0000000000000980","DOIUrl":"https://doi.org/10.1097/CRD.0000000000000980","url":null,"abstract":"Pompe disease is an autosomal recessive genetic disease caused by a mutation in the acid α-glucosidase (GAA) gene, which results in dysfunction of the GAA and a buildup of glycogen in lysosomes. Recently, new research has found additional causes of the disease pathology, such as the role of autophagy. Currently, the standard of care is enzyme replacement therapy (ERT). ERT has been proven to increase survival in Pompe disease as well as improve pulmonary and motor tests compared to no treatment. However, some patients do not see improvement from these treatments, and the life expectancy and quality of life of patients with Pompe disease remain low. New research focuses on gene therapy with an adeno-associated virus-mediated α-glucosidase vector (rAAV1-hGAA or rAAV1-CMV-hGAA). Gene therapy has the potential to provide longer-term treatment for patients with Pompe disease. Patients commonly experience side effects from the procedure such as pneumothorax, capnothorax, pericardial effusion, pleural effusion, lung contusion, etc. In phase I/II trials, the gene therapy has been found to be safe, result in sustained GAA levels, and have some improvements in pulmonary function. Many clinical trials are currently ongoing.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Conduction System Pacing in Heart Failure: Current Evidence and Future Directions. 传导系统起搏在心力衰竭中的作用：目前的证据和未来的方向。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-02 DOI: 10.1097/CRD.0000000000000993

Hadrian Hoang-Vu Tran, Audrey Thu, Anu Radha Twayana, Axel Fuertes, Marco Gonzalez, Marina Basta, Ashwini Mahadevaiah, Krutagni Adwait Mehta, Damien Islek, Maggie James, William H Frishman, Wilbert S Aronow

{"title":"The Role of Conduction System Pacing in Heart Failure: Current Evidence and Future Directions.","authors":"Hadrian Hoang-Vu Tran, Audrey Thu, Anu Radha Twayana, Axel Fuertes, Marco Gonzalez, Marina Basta, Ashwini Mahadevaiah, Krutagni Adwait Mehta, Damien Islek, Maggie James, William H Frishman, Wilbert S Aronow","doi":"10.1097/CRD.0000000000000993","DOIUrl":"https://doi.org/10.1097/CRD.0000000000000993","url":null,"abstract":"Conduction system pacing (CSP), including His bundle pacing and left bundle branch area pacing, offers a promising approach to treating heart failure (HF) with conduction system disease. This review examines the evidence supporting CSP as an alternative to traditional biventricular pacing in improving outcomes for HF patients. Studies were reviewed focusing on CSP's clinical efficacy in patients with left bundle branch block (LBBB) and those who are nonresponders to cardiac resynchronization therapy. Findings suggest that CSP enhances electrical and mechanical synchronization, improving left ventricular ejection fraction, reducing QRS duration, and leading to better clinical outcomes, including decreased HF-related hospitalizations and reduced all-cause mortality. Despite these benefits, technical challenges such as lead placement and device-related complications remain. The review concludes that CSP may offer significant advantages over conventional cardiac resynchronization therapy, particularly in patients with persistent conduction delays or myocardial scar. However, larger randomized controlled trials are needed to validate the long-term efficacy and safety of CSP across diverse patient populations. Future advancements in pacing technologies and personalized treatment strategies are expected to further refine CSP's role in HF management.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating Outcomes of Pediatric Stroke due to Extracranial Arterial Dissection: A Population-Based Cross-Sectional Study of 11,000 Patients. 颅内外动脉夹层所致儿童卒中的预后调查：一项基于人群的横断面研究，共纳入11000例患者。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2025-04-22 DOI: 10.1097/CRD.0000000000000927

Ankita Jain, Helen Ng, Galadu Subah, Michael Fortunato, Eris Spirollari, Ariel Sacknovitz, Alis J Dicpinigaitis, Fawaz Al-Mufti, Rolla Nuoman

{"title":"Investigating Outcomes of Pediatric Stroke due to Extracranial Arterial Dissection: A Population-Based Cross-Sectional Study of 11,000 Patients.","authors":"Ankita Jain, Helen Ng, Galadu Subah, Michael Fortunato, Eris Spirollari, Ariel Sacknovitz, Alis J Dicpinigaitis, Fawaz Al-Mufti, Rolla Nuoman","doi":"10.1097/CRD.0000000000000927","DOIUrl":"10.1097/CRD.0000000000000927","url":null,"abstract":"Extracranial arterial dissection (EAD) involving the carotid and vertebral arteries poses a significant risk for acute ischemic stroke (AIS) in children and often presents challenges in diagnosis. The investigation of outcomes and interventions in pediatric AIS secondary to EAD remains significantly underexplored. This retrospective cohort study examines the clinical outcomes of pediatric patients experiencing EAD. The National Inpatient Sample was queried from 2015 to 2019 for pediatric patients aged 0-18 years with a primary diagnosis of AIS, using International Classification of Disease 10th Edition diagnostic codes. Demographic characteristics, comorbidities, acute stroke indices, inpatient complications, and interventions were compared. Outcome measures included length of stay, discharge disposition, and inpatient mortality. Of a total of 11,945 patients diagnosed with AIS, 285 (2.4%) had stroke secondary to EAD. Pediatric patients with EAD-AIS were less likely to have hypertension ( P = 0.007), pneumonia ( P = 0.033), acute kidney injury ( P = 0.024), tracheostomy ( P = 0.007), and mechanical ventilation ( P = 0.003), compared with pediatric patients with strokes due to other etiologies. These patients were also more likely to be adolescents (13-18 years old) and to undergo endovascular thrombectomy and extracranial carotid or vertebral artery stenting ( P < 0.001). In a cohort matched for demographics and severity, EAD-AIS patients had a shorter length of stay ( P < 0.001) and decreased likelihood of in-patient mortality ( P < 0.001), but no significant difference in the likelihood of routine discharge home ( P = 0.054). Identification of potential risk factors for EAD in pediatric patients may help physicians optimize care and prevention strategies for pediatric patients at risk for EAD.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"302-305"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transthyretin Amyloid Cardiomyopathy: A Review of Approved Pharmacotherapies. 转甲状腺素淀粉样心肌病：已批准的药物治疗综述。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 DOI: 10.1097/CRD.0000000000000985

Mohammed Kallash, William H Frishman

{"title":"Transthyretin Amyloid Cardiomyopathy: A Review of Approved Pharmacotherapies.","authors":"Mohammed Kallash, William H Frishman","doi":"10.1097/CRD.0000000000000985","DOIUrl":"https://doi.org/10.1097/CRD.0000000000000985","url":null,"abstract":"Transthyretin (TTR) amyloidosis (ATTR) occurs due to misfolding and aggregation of TTR protein in numerous organs and tissues, resulting in various clinical presentations including cardiomyopathy and polyneuropathy. The pathophysiology of ATTR cardiomyopathy is characterized by TTR deposition in the interstitial space between cardiac myocytes, contributing to microvascular dysfunction and cardiac myocyte injury and necrosis. As the misfolded TTR protein accumulates in cardiac tissue, it results in impaired diastolic function, progressive ventricular wall thickening, and impaired longitudinal systolic function. Understanding the pathophysiology of ATTR cardiomyopathy has allowed for the development of pharmacotherapies that target the disease process, including the identification of a stabilizing TTR gene mutation, threonine119methionine (T119M), that confers resistance towards amyloidogenesis. In 2019, the Food and Drug Administration approved tafamidis for the treatment of ATTR cardiomyopathy due to its ability to stabilize the TTR tetramer and prevent dissociation into monomers that subsequently cause amyloidosis. In 2024, acoramidis was approved for ATTR cardiomyopathy as a novel TTR stabilizer structurally designed to mimic the stabilizing effects of the T119M mutation by binding selectively and with high affinity to TTR, preventing the dissociation of TTR tetramer into monomers and aggregation into amyloid fibrils. In 2025, vutrisiran, a small interfering ribonucleic acid that cleaves TTR messenger RNA and decreases the production of TTR protein, was approved for use in ATTR cardiomyopathy. In their clinical trials, these approved therapies demonstrated significant mortality and morbidity benefits in patients with ATTR cardiomyopathy, including a decrease in cardiovascular events, hospitalizations, and functional status.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Direct Oral Anticoagulants: An Overview of Indications, Pharmacokinetics, Comorbidities, and Perioperative Management. 直接口服抗凝剂：适应症、药代动力学、合并症和围手术期管理综述。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2023-09-27 DOI: 10.1097/CRD.0000000000000618

Errol Moras, Kruti Gandhi, Mohammad Khan, Adlyn Moras, James Choi, William H Frishman, Wilbert S Aronow

{"title":"Direct Oral Anticoagulants: An Overview of Indications, Pharmacokinetics, Comorbidities, and Perioperative Management.","authors":"Errol Moras, Kruti Gandhi, Mohammad Khan, Adlyn Moras, James Choi, William H Frishman, Wilbert S Aronow","doi":"10.1097/CRD.0000000000000618","DOIUrl":"10.1097/CRD.0000000000000618","url":null,"abstract":"Direct oral anticoagulants (DOACs) have catalyzed a significant paradigm shift in the landscape of anticoagulant therapy, emerging as pivotal agents for the prevention of stroke in atrial fibrillation and venous thromboembolism. Although the absolute advantages of DOACs over vitamin K antagonists (VKAs) may appear modest, clinical guidelines advocate for their preference across various indications, attributing this endorsement to their ease of administration and heightened safety. DOACs find application in preventing and treating diverse cardiovascular conditions. With the progressive expansion of DOAC utility, clinicians encounter intricate decisions concerning the selection of appropriate agents, determination of optimal treatment duration, and utilization within specialized patient subgroups. Extensive evidence has substantiated the noninferiority or superiority of DOACs compared with VKAs in both prophylaxis and treatment of thromboembolic events. Notably, routine monitoring to evaluate treatment efficacy is not mandated for DOACs; however, they exhibit interactions with co-administered drugs and exert influence on functional coagulation assessments. This review aims to synthesize existing literature, encompassing the delineation of appropriate clinical indications, tailored employment in patients with specific concurrent conditions, needs in monitoring parameters, seamless transitions during shifts between anticoagulant regimens, and a glimpse into forthcoming perspectives in this evolving field.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"312-318"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41100724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultra-Early Blood Pressure Control in Acute Intracerebral Hemorrhage. 急性脑出血的超早期血压控制。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2025-03-24 DOI: 10.1097/CRD.0000000000000904

Janelle O Poyant, Brianne M Ritchie

{"title":"Ultra-Early Blood Pressure Control in Acute Intracerebral Hemorrhage.","authors":"Janelle O Poyant, Brianne M Ritchie","doi":"10.1097/CRD.0000000000000904","DOIUrl":"10.1097/CRD.0000000000000904","url":null,"abstract":"Acute intracerebral hemorrhage (ICH) remains one of the most devastating neurological emergencies, with blood pressure (BP) management in the early hours playing a pivotal role in determining patient outcomes. Emerging evidence suggests that ultra-early BP control-intervening within minutes to 2 hours of symptom onset-has the potential to reduce secondary brain injury and improve survival. Yet, despite this evidence, current clinical practice is often inconsistent, and there is no universally agreed-upon approach for managing BP in the acute phase of ICH. We advocate for ultra-early BP intervention as a standard of care in ICH, as it offers a clear opportunity to mitigate damage and to enhance recovery. We contend that current BP management protocols are often too conservative and fail to recognize the critical importance of acting swiftly. The first few hours represent a unique window in which targeted interventions, such as continuous infusion intravenous antihypertensives, may limit hematoma expansion and stabilize cerebral perfusion pressure. However, achieving optimal outcomes requires more than just aggressive treatment-it demands a tailored approach to BP control, accounting for individual patient factors, evolving clinical conditions, and operational aspects of care. We advocate for a paradigm shift toward prioritizing ultra-early intervention, supported by clear, evidence-based protocols and real-time decision-making.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"287-290"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Paradigm Shift in Hydrocephalus Management: The Promise of Endovascular Cerebrospinal Fluid Diversion. 脑积水治疗的范式转变：血管内脑脊液转移的前景。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2025-03-26 DOI: 10.1097/CRD.0000000000000886

Abdelaziz Amllay, Charles C Matouk

{"title":"A Paradigm Shift in Hydrocephalus Management: The Promise of Endovascular Cerebrospinal Fluid Diversion.","authors":"Abdelaziz Amllay, Charles C Matouk","doi":"10.1097/CRD.0000000000000886","DOIUrl":"10.1097/CRD.0000000000000886","url":null,"abstract":"Normal pressure hydrocephalus (NPH) predominantly affects the elderly and is the most common form of adult-onset hydrocephalus. Clinically, it is characterized by Hakim's triad-gait disturbance, dementia, and urinary incontinence-and is marked by abnormal cerebrospinal fluid accumulation without increased intracranial pressure. Although the exact pathophysiology is not fully understood, proposed mechanisms include glymphatic dysfunction, blood-brain barrier disruption, and hypoperfusion. In carefully selected patients, the standard treatment, ventriculoperitoneal shunting, can provide significant improvement in gait stability and urinary incontinence, and to a lesser extent, cognitive decline. However, ventriculoperitoneal shunting carries substantial risks, including infection, need for revision, and over-drainage, highlighting the urgent need for safer, more effective treatment options. CereVasc's eShunt System is a promising, minimally invasive alternative. This 3-cm biomimetic device is deployed via a percutaneous transvenous approach in the inferior petrosal sinus. It is deployed across the wall of the venous sinus and dura mater and thereby mimics the function of an arachnoid granulation by passively diverting cerebrospinal fluid from the cerebellopontine angle cistern into the internal jugular vein. It is hoped that this minimally invasive approach will reduce the risks associated with conventional shunting. This brief opinion piece reviews NPH, the challenges of current treatments, and the potential of the eShunt System. Preliminary data from ongoing clinical trials suggest that the eShunt System may represent a minimally invasive treatment option for patients with NPH and other forms of communicating hydrocephalus. Furthermore, this technology may serve as a platform for advanced central nervous system drug delivery, broadening its impact on neurointerventional therapies.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"294-297"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular Manifestations of Hemochromatosis: A Review of Pathophysiology, Mechanisms, and Treatment Options. 血色素沉着症的心血管表现：病理生理学、机制和治疗方案综述。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2023-10-26 DOI: 10.1097/CRD.0000000000000622

Shamim Ahmed, Stephen J Peterson, Manish A Parikh, William H Frishman

引用次数: 0

Innovation in the Management of Delayed Cerebral Ischemia in Subarachnoid Hemorrhage. 蛛网膜下腔出血迟发性脑缺血治疗的创新。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2025-04-17 DOI: 10.1097/CRD.0000000000000921

Pankajavalli Ramakrishnan, Ankita Jain, Eris Spirollari, Ariel Sacknovitz, Fawaz Al-Mufti

{"title":"Innovation in the Management of Delayed Cerebral Ischemia in Subarachnoid Hemorrhage.","authors":"Pankajavalli Ramakrishnan, Ankita Jain, Eris Spirollari, Ariel Sacknovitz, Fawaz Al-Mufti","doi":"10.1097/CRD.0000000000000921","DOIUrl":"10.1097/CRD.0000000000000921","url":null,"abstract":"Aneurysmal subarachnoid hemorrhage is one of the feared stroke subtypes with a high degree of morbidity and mortality. Even after the initial treatment of the ruptured aneurysm, patients remain critically ill due to numerous neurologic and systemic sequalae. Among them is cerebral vasospasm, which is a key contributor in the development of delayed cerebral ischemia (DCI). Whereas prevention of DCI with oral nimodipine is standard of care, neurointerventional strategies in the management of DCI are varied. Chemical angioplasty with intra-arterial vasodilators has been a conventional approach when noninvasive medical management fails but is associated with the need for retreatment and therefore felt to be least durable. Balloon angioplasty is also another classically employed, but less frequent intervention, and is limited by utility in the proximal arterial segment, a narrower safety profile, and challenging navigability. More recently, the use of retrievable stents is emerging as a novel strategy with the advantages of improved safety profile, and navigability to treat more distal segments. Here, a selective overview of some of these classic and innovative neurointerventional strategies is presented in the treatment of symptomatic vasospasm/DCI.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"298-301"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factor XI/XIa Inhibitors: A New Approach to Anticoagulation.

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2023-12-01 DOI: 10.1097/CRD.0000000000000624

Harris Z Whiteson, William H Frishman

{"title":"Factor XI/XIa Inhibitors: A New Approach to Anticoagulation.","authors":"Harris Z Whiteson, William H Frishman","doi":"10.1097/CRD.0000000000000624","DOIUrl":"10.1097/CRD.0000000000000624","url":null,"abstract":"For more than 60 years, anticoagulation drugs have served as a mainstay in preserving and improving the cardiovascular health of patients across the globe. Functioning to reduce a patient's ability to produce blood clots, prescription rates for anticoagulants have been steadily rising year-over-year both in the United States and abroad. Despite decades of clinical usage, modern-day anticoagulants have been shown to predispose an individual to pathological bleeding. Even in seemingly benign instances of bleeding, patients on anticoagulation therapy might require intensive and expensive medical procedures or monitoring. Understanding the clinical implications of pathological bleeding, research and development of future anticoagulants seeking to minimize these effects. One emerging category of anticoagulant drugs are Factor XI/XIa (FXI) inhibitors. Targeting the coagulation cascade, clinical trials of Factor XIa inhibitors have shown promising results in preventing blood clot formation without increasing the instances of spontaneous and/or pathological bleeding events. While still in phase II and III clinical trials, and potentially years away from being implemented as standard of care, these novel drugs might have the potential to improve the safety and quality of life of patients taking anticoagulants. In this review, we discuss a brief history of anticoagulation therapy, followed by an analysis of the potential risks, benefits, and implications of Factor XI/XIa inhibitors across elements of patient care.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"306-311"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0